Latest News

Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19

Apr

28

2023

Senhwa Biosciences Announces Successful Awardee of Anticancer Pipeline, Pidnarulex, in NIH-Sponsored NExT Program

Dec

01

2022

Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer’s Talazoparib for the Treatment of Prostate Cancer

Oct

31

2022

Senhwa’s Pindnarulex in Combination Study with Pfizer’s Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

Jun

06

2022

At the 2022 AAD Annual Meeting Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma

Mar

28

2022

Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations.

Jan

25

2022

Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

Jan

20

2022

Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma

Dec

16

2021